SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently under pressure as traders react to a now-deleted claim by investor Michael Burry that rival Anthropic is disrupting the company's business model. While community sentiment is heavily polarized between long-term supporters defending the stock's fundamental moat and bears pointing to its high valuation and competition, the stock is seeing significant volatility as investors weigh the impact of these narratives ahead of upcoming earnings.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as a major momentum play, fueled by aggressive analyst price target hikes and sustained investor excitement over its role in the AI memory infrastructure cycle. While bulls are driving the stock higher on expectations of a potential stock split and supply-side shortages, a vocal segment of the community remains cautious, warning of a potential bubble and comparing the rapid price appreciation to past speculative blow-off tops.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently a focal point for investors as the company undergoes significant restructuring, including widespread layoffs, to fund an aggressive pivot toward AI-driven data center expansion. While some in the community view these moves as a strategic reallocation of capital to secure long-term growth, many investors are expressing frustration over the stock's persistent downward trend and volatility compared to broader market gains.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following the announcement of a massive $21 billion multi-year deal with Meta, alongside a $3 billion convertible note offering to fund rapid AI infrastructure expansion. The community is actively debating the trade-off between this aggressive, debt-fueled growth strategy and the potential for long-term dominance in the AI cloud sector, with many investors closely watching if the stock can overcome short-term dilution fears and resistance levels to regain triple-digit pricing.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a surge in investor confidence driven by a series of high-profile, multi-year collaboration deals with companies like Google and the integration into Elon Musk's Terafab project. The market is actively discussing a potential valuation re-rating, with traders split between bullish sentiment fueled by these strategic wins and concerns regarding the stock's recent rapid appreciation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors react to the FDA accepting the BLA resubmission for its melanoma treatment, with a PDUFA date set for April 2026. The community is actively debating the likelihood of approval following a prior Complete Response Letter, with many analyzing whether the resubmitted data sufficiently addresses previous concerns regarding trial design and efficacy.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as it faces heavy selling pressure alongside the broader SaaS sector, driven by analyst downgrades and growing market anxiety that agentic AI models could disrupt traditional subscription-based enterprise software. Despite solid fundamentals and management's confidence, the community is deeply divided between those viewing the decline as a generational buying opportunity and those fearing a long-term structural shift away from legacy platforms.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as record-breaking Q1 revenue and strong monthly sales confirm that AI infrastructure demand remains robust, effectively silencing concerns about a cooling cycle. The community is actively discussing the stock's role as a reliable 'lie detector' for the semiconductor industry, with investors closely watching capacity expansion and aggressive analyst price target hikes as bullish indicators despite ongoing geopolitical and supply-chain uncertainties.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. is currently the subject of intense speculation as buyout rumors, particularly involving potential interest from Sun Pharma, fuel volatility alongside ongoing discussions about the company's significant debt load. While some investors are betting on a turnaround driven by the recent FDA approval for Nexplanon's extended use and VTAMA trial success, others remain cautious, debating whether the stock is a deep-value opportunity or a long-term play burdened by its balance sheet.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently at the center of a intense tug-of-war as investors weigh weak quarterly revenue and EPS against a massive surge in bookings and an optimistic outlook driven by AI-related demand. While the community is sharply divided between those betting on a potential short squeeze fueled by record backlog and others warning of a major valuation correction, the stock remains a high-volatility battleground for those tracking the broader photonics and semiconductor testing supercycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The workforce reduction will be “substantially completed” by Feb. 13.&nbsp;</li><li>As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter.</li><li>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move.</li></ul>Werewolf Therapeutics, Inc. (HOWL) has decided to reduce its workforce by 64% as it seeks to lower its operating costs, the company said in a filing with the Securities and Exchange Commission on Friday.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001785530/000119312526051455/d110809d8k.htm">said</a> that the decision was approved by its Board of Directors on Feb. 9, and the workforce reduction will be “substantially completed” by Feb. 13.As part of the workforce reduction efforts, the company expects to incur a one-time charge of $4.1 million in the first quarter. The amount includes employee separation benefits, including severance and related benefits.Shares of the company rose over 4% after hours after closing down 1% in the regular trading session.<h2 class="st-heading-2">CFO &amp; CMO Exits</h2>CFO Timothy W. Trost and chief medical officer (CMO) Randi Isaacs will resign as part of the move and are entitled to severance benefits including an amount equal to nine months of their base salary, Werewolf Therapeutics said. &nbsp;However, both the executives will assist in aiding a transition of their responsibilities from time to time for up to six months. &nbsp;The company also said on Friday that it is evaluating alternatives such as strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs. It sought to raise capital in the fourth quarter of 2025 as well as the first quarter of 2026 to fund operations and has engaged in investor discussions regarding pipeline and financing, it added.However, the company said on Friday that there is no guarantee that any transaction would occur.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HOWL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HOWL">HOWL stock</a> has dropped 57% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slumps-after-fda-declines-approval-for-inherited-disorder-drug/cZRd2YMR4tK">Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Werewolf Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 

Equity

The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9. 


Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...

Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...

Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...

Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the company's stock in a transaction dated Friday, December 12th. The shares were sold at an...

Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

HOWL
Werewolf Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HOWL News

HOWLWerewolf Therapeutics Inc